Search

Danaher Corp

Închisă

SectorSănătate

191.98 -0.1

Rezumat

Modificarea prețului

24h

Curent

Minim

189.24

Maxim

193.94

Indicatori cheie

By Trading Economics

Venit

-168M

1B

Vânzări

-887M

6B

P/E

Medie Sector

39.511

62.58

EPS

2.06

Randament dividend

0.67

Marjă de profit

17.291

Angajați

58,000

EBITDA

-560M

1.5B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+14.17% upside

Dividende

By Acuity

Randament dividend

Medie Sector

0.67%

2.19%

Următoarele câștiguri

20 oct. 2026

Data viitoare de dividende

31 iul. 2026

Următoarea dată ex-dividende

25 sept. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

4B

142B

Deschiderea anterioară

192.08

Închiderea anterioară

191.98

Sentimentul știrilor

By Acuity

47%

53%

151 / 340 Clasament în Healthcare

Danaher Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 iul. 2026, 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23 iul. 2026, 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22 iul. 2026, 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21 iul. 2026, 19:41 UTC

News
Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20 iul. 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Comparație

Modificare preț

Danaher Corp Așteptări

Obiectiv de preț

By TipRanks

14.17% sus

Prognoză pe 12 luni

Medie 219.78 USD  14.17%

Maxim 240 USD

Minim 195 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruDanaher Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

17

Cumpărare

3

Păstrare

0

Vânzare

Sentiment

By Acuity

151 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat